XDF
XDF (eXtended Dwell Flat) is a unique patented elliptical head from which has been designed to increase time on existing presses without the need for expensive modifications.
Do you want to increase dwell time by 50%?
XDF (eXtended Dwell Flat) is a unique patented elliptical head from which has been designed to increase time on existing presses without the need for expensive modifications. It allows more dwell time than a D type punch on a B-type tool which helps solves compression problems without upsizing punches or investigating in a new press.
XDF runs on standard cams, giving users higher press speeds with challenging products and formulations. It also enhances tablet compaction/cohesion and can increase dwell by up to 50% over a standard punch head.
Benefits include:
- Improved Productivity
- Designed to run on standard cams
- Solve dwell time problems without upsizing punches
- More than D-type dwell on B-type punch
- Allows faster press operation
- Enhanced tablet compaction
I Holland have been developing the science behind tablet compression tooling for more than six decades of research. Development and investment has established I Holland as the pre-eminent supplier of punches and dies to producers of tablets across the globe. Our commitment to the development of innovative materials and products, combined with state of the art Quality Assurance Technology and unmatched customer service, has seen our solutions being successfully adopted by customers in more than 90 countries worldwide.
Contact Details :
I Holland Ltd
Website: www.tablettingscience.com
E-mail: info@iholland.co.uk
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
